促肝细胞生长素治疗慢性乙型肝炎重度及重型的疗效评价

Evaluation of HGF in treating patients with chronic advanced hepatitis and chronic liver failure caused by HBV

目的评价促肝细胞生长素治疗慢性乙型病毒性肝炎(重度及重症型)的临床疗效。方法将138例重度或重型慢性乙型肝炎患者随机分成观察组和对照组,两组基本用药相同,观察组加用促肝细胞生长素治疗25天,比较两组治疗前后总胆红素(TBIL)、凝血酶原活动度(PTA)和胆碱酯酶(CHE)的水平,统计病死率。结果疗程结束后。观察组与对照组的TBIL、PTA、CHE水平经统计学处理差异均无显著性(P>0.05);重症肝炎观察组病死率为43.2％,对照组为41.94％,两者比较亦无明显差异(P>0.05)。结论促肝细胞生长素治疗重度和重症型慢性乙型肝炎,疗效不确切。同时难以降低重症肝炎的病死率。

Objective To evaluate the clinical effect of hepatocyte growth - promoting factors (pHCF) in treating patients with chronic advanced hepatitis and chronic liver failure caused by HBV.Methods 138 patients were randomly divided into two groups, the treated group and the controlled group. With the same elementary therapeutic project for the two groups, HCF was added to the treatment of patients in the treated group, which lasted for 25 days. The serum levels of total bilirubin (TBIL), prothrombin time activity (PTA), serum cholinesterase (CHE) were respectively compared in the two groups before and after treatment. Furthermore, the mortality rate in each group was calculated. Results The patients' serum levels of TBIL, PTA, CHE in both groups after treatment had no significant difference compared to those before treatment (P> 0.05). The mortality rates of the patients with chronic liver failure in treated group and controlled group were respectively 43.20% and 41.94%, which had no significant difference (P>0.05) .Conclusion There is no definite value for pHGF in treatment of patients with chronic advanced hepatitis and chronic liver failure caused by HBV. Moreover, the treatment with pHCF couldn't decrease the mortality rate of the patients with chronic liver failure.